Investigational Drug Information for Darinaparsin
✉ Email this page to a colleague
What is the drug development status for Darinaparsin?
Darinaparsin is an investigational drug.
There have been 12 clinical trials for Darinaparsin.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2006.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, T-Cell, Peripheral, and Lymphoma, T-Cell. The leading clinical trial sponsors are Ziopharm, Solasia Pharma K.K., and Synex Consulting Korea Ltd.
Summary for Darinaparsin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 99 |
| WIPO Patent Applications | 73 |
| Japanese Patent Applications | 41 |
| Clinical Trial Progress | Phase 2 (2006-12-01) |
| Vendors | 26 |
Recent Clinical Trials for Darinaparsin
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Solasia Pharma K.K. | Phase 2 |
| A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea | Synex Consulting Korea Ltd. | Phase 1 |
| A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea | Solasia Pharma K.K. | Phase 1 |
Clinical Trial Summary for Darinaparsin
Top disease conditions for Darinaparsin
Top clinical trial sponsors for Darinaparsin
US Patents for Darinaparsin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
